Intrahepatic hypothyroidism in MASLD: Role of liver-specific thyromimetics including resmetirom
-
Published:2024-05
Issue:5
Volume:18
Page:103034
-
ISSN:1871-4021
-
Container-title:Diabetes & Metabolic Syndrome: Clinical Research & Reviews
-
language:en
-
Short-container-title:Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Author:
Kuchay Mohammad ShafiORCID,
Isaacs Scott,
Misra Anoop
Reference59 articles.
1. Destined to develop NAFLD? The predictors of fatty liver from birth to adulthood;Valenti;J Hepatol,2016
2. NAFLD in some common endocrine diseases: prevalence, pathophysiology, and principles of diagnosis and management;Lonardo;Int J Mol Sci,2019
3. Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease;Guy;Hepatology,2012
4. Resmetirom: an orally administered, small molecule, liver-directed, β-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis;Karim;touchREV Endocrinol,2023
5. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial;Harrison;Lancet,2019
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献